Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.35 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360385 | 0.85 | HIF1A (0.36) | HIF1AAKR1C3AKR1C2CTSACETP | |
| SCHEMBL1262057 | 0.77 | CTSS (0.34) | CYP2D6CYP2C9 | |
| SCHEMBL1261620 | 0.76 | CTSS (0.33) | CYP2D6CYP2C9 | |
| SCHEMBL1262387 | 0.75 | CTSS (0.33) | CYP2D6CYP2C9 | |
| SCHEMBL5936510 | 0.74 | NPC1 (0.35) | — | |
| SCHEMBL4360390 | 0.71 | HIF1A (0.36) | HIF1AAKR1C3AKR1C2CTSACETP | |
| SCHEMBL1261415 | 0.71 | HIF1A (0.38) | HIF1AAKR1C3AKR1C2MAPTBCHE | |
| SCHEMBL1262375 | 0.70 | ALDH1A1 (0.47) | HIF1AL3MBTL1MAPTBCHEACHE | |
| SCHEMBL1262376 | 0.70 | ALDH1A1 (0.47) | HIF1AL3MBTL1MAPTBCHEACHE | |
| SCHEMBL2493749 | 0.70 | ALDH1A1 (0.59) | HIF1ATDP1MAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072509-A1 | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | disclosed |